Table 2. Primary Endpoint (Major Adverse Cardiovascular Events) of Completed Trials.

PositiveHR, hazard ratio; CI, confidence interval; SGLT2, sodium-glucose cotransporter 2; EMPA-REG, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Temoving Excess Glucose; CANVAS, Canagliflozin Cardiovascular Assessment Study; DECLARE-TIMI 53, Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 53; GLP-1RA, glucagon-like peptide 1 receptor agonist; ELIXA, Evaluation of Lixisenatide in Acute Coronary Syndrome; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; SUSTAIN-6, Semaglutide in Subjects with Type 2 Diabetes; EXSCEL, Exenatide Study of Cardiovascular Event Lowering; HARMONY, Albiglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease.